You just read:

Takeda and TiGenix Announce Publication in The Lancet of 24-Week Results of the Phase 3 ADMIRE-CD Trial Investigating Cx601 in the Treatment of Complex Perianal Fistulas in Patients with Crohn's Disease

News provided by

Takeda Pharmaceutical Company Limited

Aug 02, 2016, 02:00 ET